Preclinical efficacy for molecules targeting the cleavage and polyadenylation complex component CPSF3 (Tao et al., 2024; Liu et al., 2023) has shown efficacy in leukemia (Ross et al., 2020), Ewing’s sarcoma (Ross et al., 2020), ovarian (Shen et al., 2023), and pancreatic cancer models (Alahmari et al., 2024). Here, CPSF3 is linked to Ewing sarcoma.